Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis

Company Overview

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..

Key Stats

• Today's Range: $19.00 to $19.00
• 50-Day Range: $18.20 to $19.00
• 52-Week Range: $8.82 to $21.86
• Volume: N/A
• Average Volume: 1.36 million shs
• Market Capitalization: $794.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ICPT Stock Analysis - Frequently Asked Questions

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.42. Intercept Pharmaceuticals's revenue for the quarter was up 16.6% on a year-over-year basis.

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intercept Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Sarepta Therapeutics (SRPT), Netflix (NFLX), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 8/02/2023
• Today: 1/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ICPT
• CUSIP: 45845P10
• CIK: 1270073
• Web: www.interceptpharma.com
• Phone: (646) 747-1000
• Fax: 646-747-1001
• Employees: 341
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $221.82 million
• Net Margins: -19.39%
• Pretax Margin: -18.09%
• Return on Equity: -77.48%
• Return on Assets: -11.99%

Debt

• Debt-to-Equity Ratio: 3.12
• Current Ratio: 4.22
• Quick Ratio: 2.52

Sales & Book Value

• Annual Sales: $285.71 million
• Price / Sales: 2.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.72 per share
• Price / Book: 11.05

Miscellaneous

• Outstanding Shares: 41,830,000
• Free Float: 39,192,000
• Market Cap: $794.77 million
• Optionable: Optionable
• Beta: 0.88